Denying hope and health to Canadians with rare disorders

Manufacturers must overcome several federal government hurdles before patients have access to drugs

Denying hope and health to Canadians with rare disordersThe federal government has proposed major changes to the role of the Patent Medicine Prices Review Board (PMPRB), whose primary function is to ensure that maximum Canadian prices for patented medicines aren’t excessive. The changes, due to come into effect in 2019, will impact all new drugs but especially those for patients with rare disorders…